Found 4 bookmarks
Custom sorting
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-50 and 50-70 years old.
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-50 and 50-70 years old.

PICOBOO randomized trial, evaluating second boosters after mRNA priming. 1) novavax is more durable 2) mRNA vaccines have higher antibody responses 3) novavax has fewer side effects

Pfizer antibody levels drop around 40% between 1 month to 3 months post vax. Moderna is less, w/ a 14% drop in younger adults, 26% decline in older adults. Novavax had only a 3% decline in younger adults and 17% in older adults.

#vaccine#MRNA#Novavax#booster#PICOBOO
·journalofinfection.com·
The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-50 and 50-70 years old.
Antigenic imprinting dominates humoral responses to new variants of SARS-CoV-2 in a hamster model of COVID-19
Antigenic imprinting dominates humoral responses to new variants of SARS-CoV-2 in a hamster model of COVID-19

Study at KU Leuven on hamsters finds that immunity from XBB.1.5 COVID-19 vaccine favors the original strain, limiting antibody response to newer variants like JN.1.

Highlights the challenge of updating vaccines for evolving SARS-CoV-2.

#vaccine#antibodies#immune system#antigenic imprinting#MRNA
·biorxiv.org·
Antigenic imprinting dominates humoral responses to new variants of SARS-CoV-2 in a hamster model of COVID-19
Why protective antibodies fade after COVID-19 vaccines
Why protective antibodies fade after COVID-19 vaccines

While effective at preventing severe COVID-19, the protection you get from mRNA vaccines can fade within months.

Long-lasting immune cells that fight SARS-CoV-2 aren't usually found in mRNA-vaccinated people, unlike the immune cells for tetanus and flu.

#vaccine#MRNA#antibodies
·nih.gov·
Why protective antibodies fade after COVID-19 vaccines
An important study by F. Eun-Hyung Lee's team shows that long lived plasma cells (the source of long-term circulating antibodies) fail to establish after mRNA vaccination (even combined with SARS-CoV-2 infection). 🧵 (1/)
An important study by F. Eun-Hyung Lee's team shows that long lived plasma cells (the source of long-term circulating antibodies) fail to establish after mRNA vaccination (even combined with SARS-CoV-2 infection). 🧵 (1/)
“In summary, this study shows that for some reason, vaccination against Spike with mRNA vaccine (even combined with infection) fails to establish long lived plasma cells that provide IgG against the virus long term.”
#vaccine#MRNA#analysis#Discussion#Akiko Iwasaki
·x.com·
An important study by F. Eun-Hyung Lee's team shows that long lived plasma cells (the source of long-term circulating antibodies) fail to establish after mRNA vaccination (even combined with SARS-CoV-2 infection). 🧵 (1/)